Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Exercise program aims to ease chest pain in hidden heart condition

NCT ID NCT05810051

Disease control Sponsor: CoreAalst BV Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a 36-session cardiac rehabilitation program (exercise plus education) can improve quality of life in people with coronary microvascular disease, a condition where small heart vessels don't work properly. About 204 participants with angina and confirmed microvascular dysfunction will be randomly assigned to either standard medical care or standard care plus the rehab program. The main goal is to see if the rehab group reports better quality of life and fewer angina symptoms after 4 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cardiac rehabilitation (exercise and education program)
What this could lead to
If it works, this could show that a structured exercise program improves daily life and reduces angina symptoms for people with coronary microvascular disease.
What could go wrong
This is a single-center trial with a relatively short follow-up (4 months), so results may not apply broadly. The intervention is behavioral, so adherence and long-term benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 204 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Non obstructive CAD (diameter stenosis \<50% visual or FFR \> 0.80) * Angina at presentation * Evidence of microvascular dysfunction (IMR ≥ 25) Exclusion Criteria: * Inability to give consent * Acute coronary syndrome (ACS) * Severe valve disease * Permanent AF * History of coronary artery bypass grafting (CABG) * Cardiomyopathies * Intolerance to adenosine * Hemodynamic instability * Not able to exercise

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary microvascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary microvascular disorder Microvascular Angina

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary microvascular disease

Contacts and locations

Locations

  • OLV Aalst

    Aalst, East-Flanders, 9300, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.